Uncategorized
Pixium Vision Achieves Implantation of 10 Patients in Its Clinical Trial with Its Innovative 150 Electrodes IRIS® II Bionic Vision System
PARIS--(BUSINESS WIRE)--Regulatory News: Pixium Vision (Paris:PIX), a company developing and commercializing innovative bionic vision systems with the intention to allow patients who have lost their sight to lead more independent lives, announces completion of 10 implants in its IRIS® II study. All implanted patients will now follow their re-education program as defined in the ongoing European multi-centric study for IRIS® II which was launched in January 2016. Khalid Ishaque, CEO of Pixium, sa